Feature | Left Atrial Appendage (LAA) Occluders | August 01, 2016 | Dave Fornell

Update for LAA Occluder Technology News and Trends

Watchman, left atrial appendage closure, LAA occluder

Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in the left atrial appendage (LAA). The standard of care is use of warfarin or newer anticoagulation therapy agents, but there has been growing interest in eliminating the need for these drugs and their associated increased bleeding risks by closing off the LAA to prevent clot formation. Device therapy now exists for both open surgical and transcatheter LAA occlusion. 

Below are links to recent DAIC articles that offer an update on this cardiovascular technology area:

 

Occluding the Left Atrial Appendage (LAA)

VIDEO - Post-FDA Approval Experience of LAA Occluders at ACC.16

FDA Approves Pivotal Trial for St, Jude's Amulet LAA Occluder

American College of Cardiology Launches Left Atrial Appendage Occlusion Registry

Societies Issue Recommendations for Left Atrial Appendage Occlusion

Biosense Webster Acquires Coherex Medical LAA Occluder Technology

Medicare Will Cover Watchman Left Atrial Appendage Closure Device

AtriCure Receives FDA Clearance for New AtriClip Device

New Study Demonstrates Cost-Effectiveness of Watchman Device

Boston Scientific Receives CE Mark For Next-generation Watchman FLX LAA Closure Device

FDA Announces Safety Issues With Lariat Left Atrial Appendage (LAA) Closure Device

SentreHeart Receives CE Mark for Lariat Suture Delivery Device

AtriCure Receives CE Mark for AtriClip PRO2 Device

New Data Supports St. Jude Medical FFR and LAA Closure Technology

AtriCure Announces First Patient Enrolled in FROST Cryoanalgesia Study

SentreHEART Receives FDA Approval for AMAZE Trial of Lariat Suture Delivery Device

Valley Hospital Begins Enrollment for aMAZE Trial

AtriCure Enrolls First Patient in ATLAS Study

Role of Interventional Echocardiography in Transcatheter Structural Heart Procedures

 


Related Content

News | Left Atrial Appendage (LAA) Occluders

September 12, 2022 — Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval to ...

Home September 12, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

June 27, 2022 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias ...

Home June 28, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

April 12, 2022 – Patients who had leakage to the left atrial appendage due to incomplete device sealing after left ...

Home April 12, 2022
Home
News | Left Atrial Appendage (LAA) Occluders
February 28, 2022 – Boston Scientific Corporation has announced positive results from a new analysis assessing real ...
Home February 28, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

Home November 08, 2021
Home
Feature | Left Atrial Appendage (LAA) Occluders

September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly ...

Home September 27, 2021
Home
News | Left Atrial Appendage (LAA) Occluders

August 31, 2021 — Late-breaking data from a head-to-head clinical trial of the Amulet Left Atrial Appendage (LAA) ...

Home August 31, 2021
Home
News | Left Atrial Appendage (LAA) Occluders

August 16, 2021 — The U.S. Food and Drug Administration (FDA) approved Abbott's Amplatzer Amulet Left Atrial Appendage ...

Home August 16, 2021
Home
Feature | Left Atrial Appendage (LAA) Occluders

May 15, 2021 - Transcatheter left atrial appendage occlusion (LAAO) with a Boston Scientific Watchman device was ...

Home May 16, 2021
Home
News | Left Atrial Appendage (LAA) Occluders

May 15, 2021 — Patients with an elevated risk of stroke due to heart rhythm problems, or atrial fibrillation (AFib) ...

Home May 15, 2021
Home
Subscribe Now